Alex R. Thurman Sells 434 Shares of Glaukos Co. (NYSE:GKOS) Stock

Glaukos Co. (NYSE:GKOS) CFO Alex R. Thurman sold 434 shares of the stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $95.33, for a total value of $41,373.22. Following the completion of the transaction, the chief financial officer now directly owns 54,166 shares in the company, valued at $5,163,644.78. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Glaukos Stock Performance

Glaukos stock opened at $96.77 on Friday. The company has a debt-to-equity ratio of 0.77, a current ratio of 5.34 and a quick ratio of 4.78. The firm’s fifty day moving average price is $90.83 and its 200 day moving average price is $79.18. The company has a market capitalization of $4.79 billion, a price-to-earnings ratio of -34.81 and a beta of 1.08. Glaukos Co. has a 12-month low of $45.38 and a 12-month high of $97.77.

Glaukos (NYSE:GKOS) last issued its quarterly earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). The company had revenue of $82.40 million during the quarter, compared to the consensus estimate of $81.00 million. Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The firm’s quarterly revenue was up 15.7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.53) EPS. On average, research analysts forecast that Glaukos Co. will post -2.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Point72 Asset Management L.P. increased its stake in Glaukos by 154.8% during the fourth quarter. Point72 Asset Management L.P. now owns 1,152,600 shares of the medical instruments supplier’s stock valued at $50,346,000 after purchasing an additional 700,200 shares during the last quarter. Balyasny Asset Management L.P. boosted its holdings in shares of Glaukos by 304.3% in the 1st quarter. Balyasny Asset Management L.P. now owns 691,899 shares of the medical instruments supplier’s stock valued at $34,664,000 after buying an additional 520,758 shares during the period. Invesco Ltd. grew its position in shares of Glaukos by 45.5% during the 3rd quarter. Invesco Ltd. now owns 1,450,033 shares of the medical instruments supplier’s stock valued at $109,115,000 after buying an additional 453,756 shares during the last quarter. Norges Bank acquired a new stake in Glaukos during the fourth quarter worth about $17,593,000. Finally, Iron Triangle Partners LP bought a new position in Glaukos in the second quarter worth about $22,075,000. Institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Piper Sandler raised their price objective on Glaukos from $90.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, December 22nd. Stifel Nicolaus restated a “buy” rating and issued a $110.00 price target on shares of Glaukos in a report on Wednesday. StockNews.com downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 27th. JPMorgan Chase & Co. raised shares of Glaukos from a “neutral” rating to an “overweight” rating and raised their target price for the company from $66.00 to $91.00 in a research note on Thursday, December 21st. Finally, Wells Fargo & Company upped their price target on shares of Glaukos from $83.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, February 22nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $98.30.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.